PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more
PT Kalbe Farma Tbk (PTKFF) - Total Liabilities
Latest total liabilities as of September 2025: $5.27 Trillion USD
Based on the latest financial reports, PT Kalbe Farma Tbk (PTKFF) has total liabilities worth $5.27 Trillion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PT Kalbe Farma Tbk - Total Liabilities Trend (2005–2024)
This chart illustrates how PT Kalbe Farma Tbk's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PT Kalbe Farma Tbk Competitors by Total Liabilities
The table below lists competitors of PT Kalbe Farma Tbk ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sally Beauty Holdings Inc
NYSE:SBH
|
USA | $2.03 Billion |
|
Fujian Funeng Co Ltd
SHG:600483
|
China | CN¥20.37 Billion |
|
Peker Gayrimenkul Yatirim Ortakligi AS
IS:PEKGY
|
Turkey | TL3.30 Billion |
|
Shandong Weigao Group Medical Polymer Company Limited
F:UK2
|
Germany | €10.45 Billion |
|
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
|
Canada | CA$2.44 Billion |
|
Progyny Inc
NASDAQ:PGNY
|
USA | $226.39 Million |
|
Zeon Corporation
PINK:ZEOOY
|
USA | $187.86 Billion |
|
Technogym SpA
LSE:0RG1
|
UK | €410.90 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down PT Kalbe Farma Tbk's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PT Kalbe Farma Tbk's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PT Kalbe Farma Tbk (2005–2024)
The table below shows the annual total liabilities of PT Kalbe Farma Tbk from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.84 Trillion | +22.90% |
| 2023-12-31 | $3.94 Trillion | -23.45% |
| 2022-12-31 | $5.14 Trillion | +16.89% |
| 2021-12-31 | $4.40 Trillion | +2.62% |
| 2020-12-31 | $4.29 Trillion | +20.48% |
| 2019-12-31 | $3.56 Trillion | +24.81% |
| 2018-12-31 | $2.85 Trillion | +4.75% |
| 2017-12-31 | $2.72 Trillion | -1.45% |
| 2016-12-31 | $2.76 Trillion | +0.15% |
| 2015-12-31 | $2.76 Trillion | +5.77% |
| 2014-12-31 | $2.61 Trillion | -7.37% |
| 2013-12-31 | $2.82 Trillion | +37.57% |
| 2012-12-31 | $2.05 Trillion | +16.36% |
| 2011-12-31 | $1.76 Trillion | +39.51% |
| 2010-12-31 | $1.26 Trillion | -25.49% |
| 2009-12-31 | $1.69 Trillion | +24.46% |
| 2008-12-31 | $1.36 Trillion | +21.20% |
| 2007-12-31 | $1.12 Trillion | +3.79% |
| 2006-12-31 | $1.08 Trillion | -40.69% |
| 2005-12-31 | $1.82 Trillion | -- |